

1 **Integrated methylome and phenome study of the circulating proteome**

2 **reveals markers pertinent to brain health**

3 Danni A Gadd¹, Robert F Hillary¹, Daniel L McCartney¹, Liu Shi², Aleks Stolicyn³, Neil Robertson⁴,
4 Rosie M Walker⁵, Robert I McGeachan⁶, Archie Campbell¹, Shen Xueyi³, Miruna C Barbu³, Claire
5 Green³, Stewart W Morris¹, Mathew A Harris³, Ellen V Backhouse⁵, Joanna M Wardlaw^{5,7,8,9}, J
6 Douglas Steele¹⁰, Diego A Oyarzún^{11,12,13}, Graciela Muniz-Terrera¹⁴, Craig Ritchie¹⁴, Alejo Nevado-
7 Holgado², Tamir Chandra⁴, Caroline Hayward^{1,15}, Kathryn L Evans¹, David J Porteous¹, Simon R
8 Cox^{16,17}, Heather C Whalley³, Andrew M McIntosh³, Riccardo E Marioni^{1,†}

9 ¹ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU

10 ² Department of Psychiatry, University of Oxford, UK, OX3 7JX

11 ³ Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, EH10 5HF, UK

12 ⁴ MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU

13 ⁵ Centre for Clinical Brain Sciences, Chancellor's Building, 49 Little France Crescent, Edinburgh BioQuarter, Edinburgh, EH16 4SB

14 ⁶ Centre for Discovery Brain Sciences, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK

15 ⁷ Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

16 ⁸ Edinburgh Imaging, University of Edinburgh, Edinburgh, UK

17 ⁹ UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK, EH8 9JZ

18 ¹⁰ Division of Imaging Science and Technology, Medical School, University of Dundee, Dundee, UK, DD1 9SY

19 ¹¹ School of Informatics, University of Edinburgh, Edinburgh, EH8 9AB

20 ¹² School of Biological Sciences, University of Edinburgh, Edinburgh, EH3 3JF

21 ¹³ The Alan Turing Institute, 96 Euston Road, London, NW1 2DB

22 ¹⁴ Centre for Clinical Brain Sciences, Edinburgh Dementia Prevention, University of Edinburgh, Edinburgh, UK, EH4 2XU

23 ¹⁵ Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XU

24 ¹⁶ Lothian Birth Cohorts, University of Edinburgh, Edinburgh, EH8 9JZ

25 ¹⁷ Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ

26 † Corresponding author: Riccardo Marioni, riccardo.marioni@ed.ac.uk

27 **Abstract**

28

29 Characterising associations between the methylome, proteome and phenome may provide insight
30 into biological pathways governing brain health. Here, we report an integrated DNA methylation and
31 phenotypic study of the circulating proteome in relation to brain health. Methylome-wide association
32 studies of 4,058 plasma proteins are performed (N=774), identifying 2,928 CpG-protein associations
33 after adjustment for multiple testing. These were independent of known genetic protein quantitative
34 trait loci (pQTLs) and common lifestyle effects. Phenome-wide association studies of each protein
35 are then performed in relation to 15 neurological traits (N=1,065), identifying 405 associations
36 between the levels of 191 proteins and cognitive scores, brain imaging measures or *APOE* e4 status.
37 We uncover 35 previously unreported DNA methylation signatures for 17 protein markers of brain
38 health. The epigenetic and proteomic markers we identify are pertinent to understanding and
39 stratifying brain health.

40 **Introduction**

41 The health of the ageing brain is associated with risk of neurodegenerative disease ^{1,2}. Relative brain
42 age – a measure of brain health calculated using multiple volumetric brain imaging measures – has
43 recently been shown to predict the development of dementia ³. Structural brain imaging and
44 performance in cognitive tests are well-characterised markers of brain health ⁴, which clearly
45 associate with potentially modifiable traits such as body mass index (BMI), smoking and diabetes ⁵⁻⁷.
46 Understanding the interplay between environment, biology and brain health may therefore inform
47 preventative strategies.

48 Multiple layers of omics data indicate the biological pathways that underlie phenotypes. Proteomic
49 blood sampling can track peripheral pathways that may impact brain health, or record proteins
50 secreted from the brain into the circulatory system. Although proteome-wide characterisation of
51 cognitive decline and dementia risk ⁸⁻¹⁰ have been facilitated at large-scale by SOMAscan[®] protein

52 measurements, there is a need to further integrate omics to characterise brain health phenotypes.
53 Epigenetic modifications to the genome record an individual's response to environmental exposures,
54 stochastic biological effects, and genetic influences. Epigenetic changes include histone
55 modifications, non-coding RNA, chromatin remodelling, and DNA methylation (DNAm) at cytosine
56 bases, such as 5-hydroxymethylcytosine. These are implicated in changes to chromatin structure and
57 the regulation of pathways associated with neurological diseases^{11,12}. However, DNAm at cytosine-
58 guanine (CpG) dinucleotides is the most widely profiled blood-based epigenetic modification at large
59 scale.

60 Modifications to DNAm at CpG sites play differential roles in influencing gene expression at the
61 transcriptional level¹³. Additionally, DNAm accounts for inter-individual variability in circulating
62 protein levels¹⁴⁻¹⁶. Recently, through integration of DNAm and protein data, we have shown that
63 epigenetic scores for plasma protein levels – known as 'EpiScores' – associate with brain
64 morphology and cognitive ageing markers¹⁷ and predict the onset of neurological diseases¹⁸. These
65 studies highlight that while datasets that allow for integration of proteomic, epigenetic and
66 phenotypic information are rarely-available, they hold potential to advance risk stratification.
67 Integration may also uncover candidate biological pathways that may underlie brain health.

68 Associations between protein levels and DNAm at CpGs are known as protein quantitative trait
69 methylation loci (pQTM) and can be quantified by methylome-wide association studies (MWAS) of
70 protein levels. The largest MWAS of protein levels to date assessed 1,123 SOMAmer protein
71 measurements in the German KORA cohort (n=944)¹⁴. In that study, Zaghlool *et al* reported 98
72 pQTMs that replicated in the QMDiab cohort (n=344), with significant associations between DNAm
73 at the immune-associated locus *NLRC5* and seven immune-related proteins ($P < 2.5 \times 10^{-7}$).
74 This suggested that DNAm not only reflects variability in the proteome but is closely related to
75 chronic systemic inflammation. Hillary *et al* have also assessed epigenetic signatures for 281

76 SOMAmer protein measurements that were previously associated with Alzheimer's disease, in the
77 Generation Scotland cohort that we utilised in this study¹⁹. However, proteome-wide assessment of
78 pQTM has not been tested against a comprehensive spectrum of brain health traits.

79 Here, we conduct an integrated methylome- and phenome-wide assessment of the circulating
80 proteome in relation to brain health (Fig. 1), using 4,058 protein level measurements (Supplementary
81 Table 1). We characterise CpG-protein associations (pQTM) for these proteins in 774 individuals
82 from the Generation Scotland cohort using EPIC array DNAm at 772,619 CpG sites. We then
83 identify which of the 4,058 protein levels associate with one or more of 15 neurological traits (seven
84 structural brain imaging measures, seven cognitive scores and *APOE* e4 status) in 1,065 individuals
85 from the same cohort where the pQTM data are a nested subset. By integrating these datasets, we
86 probe the epigenetic signatures of proteins that are related to brain health. For these signatures, we
87 map potential underlying genetic components and chromatin interactions that may play a role in
88 protein level regulation. A YouTube video summarising the study and detailing access to the datasets
89 can be viewed at <https://www.youtube.com/channel/UCxQrFFtIIItF25YKfJTXuumQ>.

90 **Results**

91 **Methylome-wide studies of 4,058 plasma proteins**

92 We conducted MWAS to test for pQTM associations between 772,619 CpG sites and 4,058
93 circulating protein levels (corresponding to 4,235 SOMAmer measurements; Supplementary Table
94 1). The MWAS population included 774 individuals from Generation Scotland (mean age 60 years
95 [SD 8.8], 56% Female; Supplementary Table 2). 143 principal components explained 80% of the
96 cumulative variance in the 4,235 measurements (Supplementary Fig. 1 and Supplementary Table 3).
97 A threshold for multiple testing based on these components was applied across all MWAS ($P <$
98 $0.05/(143 \times 772,619) = 4.5 \times 10^{-10}$).

99 In our basic model adjusting for age, sex and available genetic pQTL effects from Sun *et al*²⁰
100 238,245 pQTM (2,107 *cis* and 236,138 *trans*, representing 0.005% of tested associations) had $P <$
101 4.5×10^{-10} (Supplementary Table 4). In our second model that further adjusted for Houseman-
102 estimated white blood cell proportions²¹, there were 3,213 associations (453 *cis* and 2,760 *trans*) that
103 had $P < 4.5 \times 10^{-10}$ (Supplementary Table 5). Smoking status and BMI are known to have well-
104 characterised DNAm signatures^{22,23}; fully-adjusted models were therefore further adjusted for these
105 factors. There were 2,928 associations (451 *cis* and 2,477 *trans*) in the fully-adjusted models
106 (Supplementary Table 6). 2,847 pQTM associations were significant in all models. Figure 2
107 summarises these findings.

108 There were 191 unique proteins with associations in the fully-adjusted models, corresponding to 195
109 SOMAmer measurements (two SOMAmers were present for CLEC11A, GOLM1, ICAM5 and
110 LRP11). Genomic inflation statistics for these 195 SOMAmer measurements (fully-adjusted
111 MWAS) are presented in Supplementary Table 7. In a sensitivity analysis, restriction of the threshold
112 for *cis* pQTM from 10Mb to 1Mb from the transcription start site of the gene encoding the protein
113 yielded 409 *cis* pQTM (a drop of 42 pQTM) in the fully-adjusted MWAS. A summary of known
114 pQTLs²⁴ and a record of whether these were available for adjustment is provided in Supplementary
115 Table 8. Characterising the genomic location of the findings, 46% of *cis* and 29% of *trans* pQTM in
116 the fully-adjusted MWAS involved CpGs positioned in either a CpG Island, Shore or Shelf
117 (Supplementary Table 6).

118 **Pleiotropic pQTM associations in the fully-adjusted MWAS**

119 Pleiotropy was observed for both CpG sites and protein levels (Fig. 3). Nineteen proteins had 10 or
120 more pQTM in the fully-adjusted MWAS (Supplementary Table 9). Of the 2,928 pQTM in the
121 fully-adjusted MWAS, 987 involved Pappalysin-1 (PAPPA) and there were a further 1,116 pQTM
122 that involved the Proteoglycan 3 Precursor (PGR3) protein. The remaining 825 pQTM involved 189

123 unique protein levels, with 434 *cis* and 391 *trans* associations (Fig. 2). Principal components
124 analyses indicated high correlations between CpGs associated with the pleiotropic proteins PAPP
125 and PRG3, whereas the CpGs involved in the remaining 825 pQTM were largely uncorrelated
126 (Supplementary Fig. 2). pQTM frequencies for the 1,837 unique CpGs selected in the fully-adjusted
127 models, with their respective genes and EWAS catalogue²⁵ lookup of epigenome-wide significant (P
128 $< 3.6 \times 10^{-8}$) phenotypic associations is presented in Supplementary Table 10. Of these CpGs, sites
129 within the *NLRC5*, *SLC7A11* and *PARP9* gene regions exhibited the highest levels of pleiotropy (Fig.
130 3).

131 The pleiotropic findings for PAPP and cg07839457 (*NLRC5* gene) replicated previous MWAS
132 results from Zaghlool *et al*¹⁴ (944 individuals, with 1,123 protein SOMAmers). Of the 98 pQTMs
133 identified by Zaghlool *et al*, 81 were comparable (both the protein and CpG sites from the 98 pQTMs
134 were available across both MWAS). Of these 81 pQTMs, 26 replicated at our significance threshold
135 ($P < 4.5 \times 10^{-10}$) with the same direction of effect, a further 16 replicated at the epigenome-wide
136 significance threshold ($P < 3.6 \times 10^{-8}$)²⁶ and a further 39 replicated at nominal $P < 0.05$
137 (Supplementary Table 11 and Supplementary Fig. 3). When accounting for 26 pQTMs that were
138 previously reported by Zaghlool *et al* and 10 pQTMs that were previously reported by Hillary *et al*
139 ^{14,19}, 2,892 of the 2,928 fully-adjusted pQTMs were novel. Of these 2,892 novel pQTMs, 1,109
140 involved the levels of 41 proteins that were measured by Zaghlool *et al* (973 pQTMs for PAPP and
141 136 additional pQTMs for the levels of 40 proteins), whereas 1,783 pQTMs involved the levels of
142 proteins that were previously unmeasured (1,116 pQTMs for PRG3 and 667 further pQTMs for 148
143 proteins).

144 **Proteome associations with brain health phenotypes**

145 We next conducted a proteome-wide association study of brain health characteristics (protein
146 PheWAS of brain imaging, cognitive scoring and *APOE* e4 status, alongside age and sex; Fig. 4).

147 Distribution plots for the seven cognitive scores and seven brain imaging phenotypes are presented in
148 Supplementary Figs. 4-5. A maximum sample of 1,065 individuals was available (mean age 59.9
149 years [SD 9.6], 59% Female; Supplementary Table 2); all 774 individuals from the pQTM study
150 were included in these analyses. A threshold for multiple testing adjustment was calculated based on
151 143 independent components that explained >80% of the 4,235 SOMAmer levels (Supplementary
152 Table 3 and Supplementary Fig. 1). This equated to $P < 0.05/(143) = 3.5 \times 10^{-4}$. The levels of 587
153 plasma proteins were associated with age and 545 were associated with sex, with 222 proteins
154 common to both phenotypes (Supplementary Table 12). When comparable associations from three
155 studies (with $N > 1000$) were tested^{20,27,28}, 97% of age and 98% of sex associations replicated in one
156 or more of studies (Supplementary Table 12).

157 There were 191 unique protein markers that had a total of 405 associations with brain health
158 characteristics (Supplementary Fig. 6 and Fig. 4a). These consisted of 95 brain imaging
159 (Supplementary Table 13), 296 cognitive test score (Supplementary Table 14) and 14 *APOE* e4
160 status (Supplementary Table 15) associations. Supplementary Table 16 stratifies these associations
161 by direction of effect and Supplementary Table 17 provides full summary statistics for all 405
162 associations. Of the seven brain morphology traits, Relative Brain Age and General Fractional
163 Anisotropy (gFA) had the largest number of associations, with 24 and 22 protein markers identified,
164 respectively. Of the cognitive score traits, Processing Speed and General Cognitive Ability scores
165 were associated with the highest number of protein markers (102 and 73, respectively). The 14
166 *APOE* e4 status associations are plotted in Supplementary Fig. 7.

167 Stratifying the 405 associations by direction of effect revealed that the majority (89%) of
168 associations indicated that higher levels of the proteins were associated with less favourable brain
169 health (Supplementary Table 16). Eighty-seven of the 405 associations involved protein levels that
170 were associated with more favourable brain health; this signature included the levels of *SLITRK1*,

171 NCAN and COL11A2. Higher levels of ASB9, RBL2, HEXB and SMPD1 associated with poorer
172 brain health. Protein interaction network analyses for the genes corresponding to the 191 protein
173 markers (Supplementary Fig. 8) indicated that many of the proteins in these signatures clustered
174 together, implying shared underlying functions. An inflammatory cluster including CRP, ITIH4, C3,
175 C5, COL11A2 and SIGLEC2 was present and higher levels of these markers were associated with
176 poorer brain health outcomes. Gene set enrichment analyses on the 191 genes corresponding to the
177 protein markers (Supplementary Fig. 9) supported the link between many of the proteins associated
178 with poorer brain health and the innate immune system, while also implicating extracellular matrix,
179 lysosomal, metabolic and additional inflammatory pathways. Tissue expression profiles of the 191
180 genes (Supplementary Fig. 10) indicated that many of the markers were expressed non-neurological
181 tissues; however, some proteins were expressed in nervous tissues. Markers such as ASB9 and
182 NCAN were found to be consistently identified across multiple brain imaging traits as markers of
183 poorer and better brain health, respectively (Supplementary Table 16). While many of the
184 associations for brain imaging measures identified proteins that were distinct from those found for
185 cognitive scores and *APOE* e4 status, 22 protein markers were associated with both a cognitive score
186 and a brain imaging trait (Fig. 4b and Supplementary Table 18). Of these 22 proteins, there were 10
187 principal components that had a cumulative variance of >80% and five components had eigenvalues
188 > 1 (Supplementary Fig. 11). Three *APOE* e4 status markers (ING4, APOB and CRP) were also
189 associated with cognitive scores (Fig. 4b).

190 **Replication of protein PheWAS associations**

191 Six of the 14 *APOE* e4 status associations replicated previous SOMAmer protein findings (N
192 SOMAmers= 4,785 and N participants=227)¹⁰, and eight novel relationships involved NEFL, ING4,
193 PAF, MENT, TMCC3, CRP, FAM20A and PEF1. Several of the markers for cognitive function
194 were identified in previous work relating Olink proteins to cognitive function (such as CPM)²⁹ and

195 work that characterised SOMAmer signatures of cognitive decline and incident Alzheimer's disease
196 (such as SVEP1)⁸. No studies have performed SOMAmer-based, whole proteome PheWAS studies
197 of the brain imaging and cognitive score traits we have profiled in a healthy ageing population that
198 were not enriched for neurodegenerative diseases. However, replication of associations from several
199 studies^{9,29,30} was found for a small subset of associations (Supplementary Table 19).

200 **Integration of the brain health proteome with our pQTM dataset**

201 Differential DNAm signatures were explored for the 191 protein markers that had $P < 3.5 \times 10^{-4}$ in
202 associations with either cognitive scores, brain imaging measures or *APOE* e4 status in the protein
203 PheWAS. Of the 191 proteins, 17 had pQTMs in the fully-adjusted MWAS. Higher levels of 15 of
204 these proteins were associated with poorer brain health, while *AMY2A* and *CST5* were associated
205 with more favourable brain health. There were a total of 35 pQTMs involving 31 unique CpGs that
206 were located within 20 distinct genes (Supplementary Table 20), with 15 *trans* (Fig. 5) and 20 *cis*
207 associations. All pQTMs were previously unreported. The 20 *cis* pQTMs involved the levels of
208 *CHI3L1*, *IL18R1*, *SIGLEC5*, *OLFM2*, *UGDH*, *CRHBP*, *AMY2A* and *CFHR1* proteins. The *trans*
209 pQTMs involved the levels of *SCUBE1*, *RBL2*, *TNFRSF1B*, *CST5*, *HEXB*, *ACY1*, *CRTAM*,
210 *SMPD1* and *RBP5* proteins.

211 Of the 20 *cis* pQTMs, 11 involved CpGs in different genes to the protein-coding gene on the same
212 chromosome, whereas the remaining 9 pQTMs involved CpGs located within the protein-coding
213 gene. Several CpG sites were associated with multiple protein levels in the *trans* pQTMs (Fig. 5).
214 DNAm at site cg06690548 in the *SLC7A11* gene was associated with *RBP5*, *ACY1* and *SCUBE1*
215 levels. The cg11294350 site in the *CHPT1* gene was associated with *HEXB* and *SMPD1* levels. The
216 cg07839457 site in the *NLRC5* gene was associated with the levels of *CRTAM* and *TNFRSF1B*.
217 There was also a protein that had several *trans* associations with multiple CpG sites; pQTMs were

218 identified between circulating RBL2 levels and cg01132052, cg0539861, cg18487916, cg27294008
219 and cg18404041, within the *NEK4/ITIH3/ITIH1* gene region of chromosome 3.

220 **Functional mapping of neurological pQTM**s

221 A lookup that integrated information from the GoDMC and eQTLGen databases assessed whether
222 pQTM

s were partially driven by an underlying genetic component. This identified methylation
223 quantitative trait loci (mQTLs) for CpGs that were associated with *CHI3L1*, *IL18R1* and *SIGLEC5*
224 and were also expression quantitative trait loci (eQTLs) for the respective protein levels
225 (Supplementary Table 20). Further visual inspection of the distributions for the 35 pQTMs indicated
226 that trimodal distributions – suggestive of unaccounted SNP effects – were present for CpGs
227 involved in seven of the pQTMs (Supplementary Fig. 12).

228 Tissue expression profiles for the 33 genes that were linked to either CpGs or proteins in the 35
229 neurological pQTM

s are summarised in Supplementary Fig. 13. Gene set enrichment for these 33
230 genes identified enrichment for immune effector pathways in a subset of 11 genes, whereas a cluster
231 of four genes (*SMPD1*, *HEXB*, *AMY2A* and *AMY2B*) were enriched for amylase and hydrolase
232 activity (Supplementary Fig. 14).

233 Of the 35 pQTM

s, seven had CpGs that were located in either a CpG Shore or Shelf position and
234 there were 13 that were located either 1500 bp or 200 bp from the TSS of the protein-coding gene
235 (Supplementary Table 20). Fifteen pQTMs involved CpGs that were located in the gene body and 7
236 were located in either the first exon or UTR regions (Supplementary Table 20).

237 Promoter-capture Hi-C and ChIP-sequencing integration was used to assess the interactions and
238 chromatin states of our pQTM

s and associated CpG loci. This analysis focused on 11 of the 20 *cis*
239 pQTMs that involved CpGs on the same chromosome as the protein-coding gene, but were located in
240 a different gene. Mapping information is presented for the seven proteins involved in these pQTMs

241 in Supplementary Figs. 15-21. In all instances, we found evidence of spatial co-localisation of these
242 genes using promoter-capture Hi-C data from brain hippocampal tissue. We attempted to
243 contextualise these sites further with ChIP-seq (ENCODE project) analyses of active chromatin
244 marks H3K27ac and H3K4me1 and repressive chromatin H3K4me3 and H3K27me3 in both
245 peripheral blood mononuclear cells (PBMCs) and brain hippocampus. ChIP-seq data suggested that
246 in many instances there were shared regulatory regions that existed across both blood and
247 hippocampal samples that were hubs for local promoter interactions. For example, promoter loops
248 were found linking the S100Z and CRHBP genes, with a signature of activating (H3Kme1 and
249 H3K27ac) and silencing (H3k27me and H3K4me3) marks (normally considered bivalent chromatin)
250 that may form the basis for shared regulation of this gene locus.

251 **Discussion**

252 We have conducted a large-scale integration of the circulating proteome with indicators of brain
253 health and blood-based DNA methylation. We characterised 191 protein markers that were
254 associated with either brain imaging measures, cognitive scores or *APOE* e4 status in an ageing
255 population. We also report methylome-wide characterisations for the SOMAscan[®] panel V.4 (4,058
256 protein measurements) in a nested subset of this population. By integrating these datasets, we
257 uncovered 35 methylation signatures for 17 protein markers of brain health. We delineated pQTM
258 CpGs that had evidence of underlying genetic influence and characterised the potential for chromatin
259 interactions for genes involved in *cis* pQTMs. As this population consists of older individuals that
260 were not enriched for neurodegenerative diseases, the markers we identify are likely indicators of
261 healthy brain ageing.

262 Many of the 191 proteins identified in the protein PheWAS were part of inflammatory clusters with
263 shared functions in acute phase response, complement cascade activity, innate immune activity and
264 cytokine pathways. Tissue expression analyses suggested that a large proportion of the 191 protein

265 markers were not expressed in the brain; this supports work suggesting that sustained peripheral
266 inflammation influences general brain health^{31,32} and accelerates cognitive decline^{8,33–35}. However, a
267 subset of proteins were expressed in the central nervous system. Given that leakage at the blood-
268 brain-barrier interface has been hallmarked as a part of healthy brain ageing^{36,37}, there is a
269 possibility that brain-derived proteins may enter the bloodstream as biomarkers. SLIT and NTRK
270 Like Family Member 1 (SLITRK1), Neurocan (NCAN) and IgLON family member 5 (IGLON5)
271 were examples of proteins expressed in brain for which higher levels associated with either larger
272 grey matter volume, larger whole brain volume, or higher general fractional anisotropy. SLITRK1
273 localises at excitatory synapses and regulates synapse formation in hippocampal neurons³⁸.
274 Neurocan (NCAN) is a component of neuronal extracellular matrix and is linked to neurite growth³⁹.
275 IGLON5 has been implicated in maintenance of blood-brain-barrier integrity and an anti-IGLON5
276 antibody disease involves the deterioration of cognitive health⁴⁰. Taken together, the protein markers
277 identified in the PheWAS may, therefore, reflect pathways that could be targeted to improve brain
278 health.

279 Integration of our fully-adjusted protein MWAS dataset revealed 35 associations between DNAm
280 and 17 protein markers of brain health (Fig. 6; Supplementary Table 20). All 35 associations were
281 novel. While this study is focused on blood DNAm – limiting generalisation to brain DNAm – many
282 of the 35 pQTM involved CpGs and proteins that have been previously implicated in neurological
283 processes. DNAm at site cg06690548 (located in the *SLC7A11* gene) was of particular interest;
284 differential DNAm at this CpG in blood has been identified as a causal candidate for Parkinson's
285 disease (N > 900 cases and N > 900 controls)⁴¹. Xc- is the cystine-glutamate antiporter encoded by
286 *SLC7A11*, which facilitates glutamatergic transmission, oxidative stress defence and microglial
287 response in the brain^{42,43} and is a target for the neurodegeneration-associated environmental
288 neurotoxin β -methylamino-L-alanine⁴¹. Analyses in the wider Generation Scotland cohort suggests
289 that cg06690548 is a site associated with alcohol consumption⁴⁴. The proteins associated with

290 cg06690548 in the subset of this cohort we assessed (ACY1, SCUBE1 and RBP5) have known links
291 to liver function⁴⁵⁻⁴⁷. DNAm at cg06690548 in blood has also been recently implicated in the largest
292 MWAS of amyotrophic lateral sclerosis (ALS) to date (6,763 cases, 2,943 controls)⁴⁸. Given that
293 ACY1, SCUBE1 and RBP5 were markers for either lower processing speed and higher relative brain
294 age, the CpG sites we identify in this study – such as cg06690548 – may be important plasma
295 markers for mediation of environmental risk on brain health that merit further exploration.
296 cg06690548 lies within the first intron of *SLC7A11*⁴¹, indicating that this site is of potential
297 functional significance.

298 The presence of *NLRC5* and various other inflammatory proteins in our neurological protein pQTM
299 suggests that the methylome may capture an inflammatory component of brain health. Many of the
300 genes corresponding to CpGs and proteins involved in the 35 pQTMs were enriched for immune
301 effector processes and were not expressed in brain. However, some markers did show evidence for
302 brain-specific expression, such as acid sphingomyelinase (SMPD1) and Hexosaminidase Subunit
303 Beta (HEXB). The HEXB and SMPD1 proteins associated with DNAm at cg11294350 (in the
304 *CHPT1* gene), are involved in neuronal lipid degradation in the brain and have been associated with
305 the onset of a range of neurodegenerative conditions⁴⁹⁻⁵². RBL2 is another protein that had partial
306 expression signals across brain regions; the *NEK4/ITIH3/ITIH1* region was the location for five
307 CpGs with differential DNAm linked to RBL2 levels. This region is implicated in schizophrenia and
308 bipolar disorder by several large-scale, genome-wide association studies (GWAS)⁵³⁻⁵⁶. Similarly,
309 the *RBL2* locus has been associated with intelligence, cognitive function and educational attainment
310 in GWAS (n > 260,000 individuals)^{33,57,58}.

311 Given that this study utilised CpGs from the Illumina EPIC array, 15 of the 31 unique CpGs did not
312 have mQTL characterisations in public databases, which primarily comprise results from the earlier
313 450K array. However, our plots showing pQTM associations suggested that for several CpGs (such

314 as cg11294350 that associated with SMPD1 and HEXB), there may be a partial genetic component
315 influencing DNAm. As mQTLs tend to explain 15-17% of the additive genetic variance of DNAm⁵⁹,
316 it is possible that the signals we isolate in these instances are partially driven by genetic loci, but are
317 also likely driven by unmeasured environmental and biological influences. In the case of SIGLEC5,
318 IL18R1 and CHI3L, mQTLs were identified that were also eQTLs, providing evidence that mQTLs
319 for these CpG sites were possible regulators of protein expression.

320 Integration of promoter-capture Hi-C chromatin interaction and ChIP-seq databases⁶⁰ provided
321 evidence for long-range interaction relationships for *cis* pQTLs with CpGs in different gene regions
322 that are proximal to the protein-coding gene of interest. This suggests that in such instances, the
323 pQTLs may reflect regulatory relationships in the 3-dimensional genomic neighbourhood. The
324 pQTLs therefore direct us towards pathways that can be tested in experimental constructs. Positional
325 information suggested that many CpGs involved in neurological pQTLs lay within 1500 bp of the
326 TSS of the respective protein-coding gene. While positional information of CpGs is thought to infer
327 whether DNAm is likely to play a role in the expression regulation of nearby genes, this is still
328 somewhat disputed. Some studies suggest that transcription factors regulate DNAm⁶¹ and
329 differential methylation at gene body locations predicts dosage of functional genes⁶². Additionally,
330 the DNAm signatures of proteins we quantify represent widespread differences across blood cells
331 that are related to circulating protein levels and are therefore not derived from the same cell-types as
332 proteins. Despite this limitation, previous work supports DNAm scores for proteins as useful markers
333 of brain health, suggesting there is merit in integrating DNAm signatures of protein levels in disease
334 stratification¹⁸.

335 Our study has several limitations. First, though full replication of our results was not possible, our
336 replication of pQTLs identified by Zaghlool *et al*¹⁴ reinforces inflammation signalling as intrinsic to
337 the methylome signature of blood proteins. This also suggests that pQTLs may be common across

338 ancestries. Second, we observed a substantial inflation for PAPP A and PRG3 proteins. While
339 comprehensive adjustment for estimated immune cells was performed and the remainder of CpGs
340 involved in pQTM s did not show high correlations (Supplementary Fig. 2), concurrently measured
341 blood components such as haemoglobin, red blood cells and platelets were not available. Future
342 studies should seek to resolve signals with more detailed blood-cell phenotyping and immune cell
343 estimates ⁶³. Third, 89% of the proteins identified in our protein PheWAS did not have epigenetic
344 pQTM s; this may be due to 1) the presence of pathways relating to neurological disease that are not
345 reflected by blood immune cell DNAm, 2) underpowered analyses, or 3) the presence of indirect
346 associations that are not captured by our MWAS approach. Fourth, the extent of non-specific and
347 cross-aptamer binding with SOMAmer technology has not been fully resolved ⁶⁴. Fifth, there are
348 likely unknown genetic influences on pQTM s. Further characterisation of pQTL s and advances in
349 multi-omic modelling techniques ¹⁵ will aid in the separation of genetic and environmental
350 influences on epigenetic signatures. Sixth, differences in blood and brain DNAm and pQTL s are
351 emerging; these indicate that blood-based markers may not fully align to biology of brain
352 degeneration ^{65,66}. However, our ChIP-seq analysis of chromatin regulation suggested that some
353 regulatory states may persist between blood and brain. Seventh, profiling DNAm signatures alone
354 cannot capture the full role of the epigenome in brain health. Integration of more diverse epigenetic
355 markers will be critical to further resolve these relationships. Finally, though we have incorporated a
356 wide portfolio of brain health measures, we recognise that these are not extensive. Increasing
357 triangulation across modalities, as we have shown here, will be useful in identifying candidate
358 markers.

359 In conclusion, by integrating epigenetic and proteomic data with cognitive scoring, brain
360 morphology and *APOE* e4 status, we identify 191 protein markers of brain health. We characterise
361 DNAm signatures for all 4,058 proteins included in the study, uncovering 35 associations between
362 differential DNAm and the levels of 17 of the protein markers of brain health outcomes. These data

363 identify candidate targets for the preservation of brain health and may inform risk stratification
364 approaches.

365 **Methods**

366 **The Generation Scotland sample population**

367 The Stratifying Resilience and Depression Longitudinally (STRADL) cohort used in this study is a
368 subset of N=1,188 individuals from Generation Scotland: The Scottish Family Health Study (GS).
369 Generation Scotland constitutes a large, family-structured, population-based cohort of >24,000
370 individuals from Scotland⁶⁷. Individuals were recruited to GS between 2006 and 2011. During a
371 clinical visit detailed health, cognitive, and lifestyle information was collected in addition to
372 biological samples. Of the 21,525 individuals contacted for participation, N=1,188 completed
373 additional health assessments and biological sampling approximately five years after GS baseline⁶⁸.
374 Of these, N=1,065 individuals had proteomic data available and N=778 of these had DNAm data
375 available. Supplementary Table 2 summarises the demographic characteristics across the two
376 groups, with descriptive statistics for phenotypes.

377 **Proteomic measurement**

378 SOMAscan® V.4 technology was used to quantify plasma protein levels. This aptamer-based assay
379 facilitates the simultaneous measurements of multiple SOMAmers (Slow Off-rate Modified
380 Aptamers)⁶⁹. SOMAmers were processed for 1,065 individuals from the STRADL subset of GS.
381 Briefly, binding between plasma samples and target SOMAmers was achieved during incubation and
382 quantification was recorded using a fluorescent signal on microarrays. Quality control steps included
383 hybridization normalization, signal calibration and median signal normalization to control for inter-
384 plate variation. Full details of quality control stages are provided in Supplementary Methods. In the
385 final dataset, 4,235 SOMAmer epitope measures were available in 1,065 individuals and these

386 corresponded to 4,058 unique proteins (classified by common Entrez gene names). Supplementary
387 Table 2 provides annotation information for the 4,235 SOMAme measurements that were available.

388 **DNAm measurement**

389 Measurements of blood DNAm in the STRADL subset of GS subset were processed in two sets on
390 the Illumina EPIC array using the same methodology as those collected in the wider Generation
391 Scotland cohort. Quality control details have been reported previously⁷⁰⁻⁷² and further details are
392 provided in Supplementary Methods. Briefly, samples were removed if there was a mismatch
393 between DNAm-predicted and genotype-based sex and all non-specific CpG and SNP probes (with
394 allele frequency > 5%) were removed from the methylation file. Probes which had a beadcount of
395 less than 3 in more than 5% of samples and/or probes in which >1% of samples had a detection
396 $P > 0.01$ were excluded. After quality control, 793,706 and 773,860 CpG were available in sets 1 and
397 2, respectively. These sets were truncated to include a total of 772,619 common probes and were
398 joined together for use in the MWAS, with 476 individuals included in set 1 and 298 individuals in
399 set 2. DNAm-specific technical variables (measurement batch and set) were adjusted in all MWAS
400 and PheWAS models.

401 **Phenotypes in Generation Scotland**

402 All phenotypes in Generation Scotland MWAS and PheWAS samples are summarised in
403 Supplementary Table 2. An epigenetic score for smoking exposure, EpiSmokEr⁷³ was calculated
404 for all individuals with DNAm. The meffil⁷⁴ implementation of the Houseman method was used to
405 calculate estimated white blood cell (WBC) proportions for Sets 1 and 2. Blood reference panels
406 were sourced from Reinus et al⁷⁵. The ‘blood gse35069 complete’ panel was used to imputed
407 measures for Monocytes, Natural Killer cells, Bcells, Granulocytes, CD4⁺T cells and CD8⁺T cells.
408 Eosinophil and Neutrophil estimates were also sourced through the ‘blood gse35069’ panel. Body
409 mass index (body weight in kilograms, divided by squared height in metres) was available for all

410 individuals, alongside depression status (defined using a research version of the Structured Clinical
411 Interview for DSM disorders (SCID) assessment), which was coded as a binary variable of no
412 history of depression (0) or lifetime episode of depression (1). Five individuals did not have
413 depression status information and were excluded from MWAS and PheWAS analyses, where
414 appropriate. *APOE* e4 status was available for 1,050 individuals. *APOE* e4 status was coded as a
415 numeric variable (e2e2 = 0, e2e3 = 0, e3e3 = 1, e3e4 = 2, e4e4 = 2). Fifteen e2e4 individuals were
416 excluded due to small sample size.

417 Scores from five cognitive tests (Supplementary Fig. 4; Supplementary Table 2) measured at the
418 clinic visit for the STRADL subset of GS were considered. Full details for the specific scores has
419 been detailed previously⁶⁸ and further details can be found in Supplementary Methods. Briefly,
420 these included the Wechsler Logical Memory Test (maximum possible score of 50), the Wechsler
421 Digit Symbol Substitution Test (maximum possible score of 133), the verbal fluency test (based on
422 the Controlled Oral Word Association task), the Mill Hill Vocabulary test (maximum possible score
423 of 44) and the Matrix Reasoning test (maximum possible score of 15). Outliers were defined as
424 scores >3.5 standard deviations above or below the mean and were removed prior to analysis. The
425 first unrotated principal component combining logical memory, verbal fluency, vocabulary and digit
426 symbol tests was calculated as a measure of general cognitive ability ('g'). General fluid cognitive
427 ability ('gf') was extracted using the same approach, but with the vocabulary test (a crystallised
428 measure of intelligence) excluded from the model. While highly similar to g, the gf score is
429 exclusive to measures such as memory and processing capability that are considered fluid. gf may
430 therefore be of greater relevance for assessing cognitive decline in ageing individuals.

431 The derived brain volume measures (Supplementary Fig. 5; Supplementary Table 2) were recorded
432 at two sites (Aberdeen and Edinburgh)⁶⁸. Brain volume data included total brain volume (ventricle
433 volumes excluded), global grey matter volume, white matter hyperintensity volume and total

434 intracranial volume. Intracranial volume was treated as a covariate to adjust for head size in all tests
435 including brain volume associations. The derived global white matter integrity measures included
436 global fractional anisotropy (gFA) and global mean diffusivity (gMD). The protocols applied to
437 derive the brain volume measures from T1-weighted scans, and white matter integrity measures from
438 diffusion tensor imaging (DTI) scans have been previously described^{35,68,76} and additional details are
439 also provided in Supplementary Methods. Brain Age was estimated using the software package
440 'brainageR' (Version 2.1; DOI: 10.5281/zenodo.3476365, available at [https://github.com/james-](https://github.com/james-cole/brainageR)
441 [cole/brainageR](https://github.com/james-cole/brainageR)), which uses machine learning and a large training set to predict age from whole-
442 brain voxel-wise volumetric data derived from structural T1 images³. This estimate was regressed
443 on chronological age to produce a measure of Relative Brain Age (residuals from the linear model).
444 Outliers for all imaging variables were defined as measurements >3.5 standard deviations above or
445 below the mean and were removed prior to analysis.

446 **Phenome-wide association analyses**

447 Prior to running protein PheWAS analyses, protein levels were transformed by rank-based inverse
448 normalisation and scaled to have a mean of zero and standard deviation of 1. Models were run using
449 the `lmekin` function in the `coxme` R package⁷⁷. This modelling strategy allows for mixed-effects
450 linear model structure with adjustment for relatedness between individuals. Models were run in the
451 maximum sample of 1,095 individuals, with the 4,235 protein levels as dependent variables and
452 phenotypes as independent variables. A random intercept was fitted for each individual and a kinship
453 matrix was included as a random effect to adjust for relatedness. Age, sex (male = 1, reference
454 female = 0), numerical *APOE* e4 status variable (e2 = 0, e3 = 1, e4 = 2), cognitive and brain imaging
455 phenotypes were included as scaled predictors. Continuous variables were scaled to mean of zero
456 and variance one. Diagnosis of depression (case = 1, reference control = 0) at the STRADL clinic
457 visit in GS was included as a covariate in all models, due to known selection bias for depression

458 phenotypes in STRADL⁶⁸. Clinic study site and protein lag group (storage time before proteomic
459 sequencing) were included as covariates in all models. Missing data were excluded from lme
460 models.

461 Three regression models were considered. For the analyses with age and sex as the predictors of
462 interest, two coefficients (β_1 and β_2) were extracted.

463 Protein level \sim Intercept + β_1 age + β_2 sex + depression + study site + lag group + (1|individual) +
464 (1|kinship)

465 For the analyses with one of cognitive scoring, *APOE* e4 status or non-volumetric brain imaging as
466 the predictor of interest, the β_3 coefficient was extracted.

467 Protein level \sim Intercept + age + sex + β_3 phenotype + depression + study site + lag group +
468 (1|individual) + (1|kinship)

469 Finally, for the models with volumetric brain imaging measures as the predictor of interest the β_4
470 coefficient was extracted.

471 Protein level \sim Intercept + age + sex + β_4 phenotype + depression + study site*ICV + lag group +
472 edited + batch + (1|individual) + (1|kinship)

473 All analyses of brain volume measures included adjustment for intracranial volume and study site as
474 main effects, in addition to the interaction between these variables. ICV was used to account for head
475 size. Imaging data processing batch, and presence or absence of manual intervention during quality
476 control (edited) variables were also included as covariates, wherever appropriate.

477 P-values for all PheWAS models were calculated in R using effect size estimates (beta) and standard
478 errors (SE) as follows: $\text{pchisq}((\text{beta}/\text{SE})^2, 1, \text{lower.tail}=\text{F})$. The Prcomp package⁷⁸ was used to
479 generate principal components for the 4,235 SOMAmer measurements (N=1,065). 143 components

480 explained >80% of the cumulative variance in protein levels (Supplementary Fig. 1 and
481 Supplementary Table 3); these components were used to derive the PheWAS multiple testing
482 adjustment threshold of $P < 0.05 / 143 = 3.5 \times 10^{-4}$. This method was chosen due to the presence of
483 high intercorrelations within the protein data.

484 **Epigenome-wide association study of protein levels**

485 Prior to running the MWAS, protein levels for 774 individuals with complete phenotypic information
486 were log transformed and regressed on age, sex, study site, lag group and 20 genetic principal
487 components (generated from multidimensional scaling of genotype data from the Illumina 610-
488 QuadV1 array). Residuals from these models were then rank-based inverse normalised and taken
489 forward as protein level data. Methylation data were in M-value format and were pre-adjusted for
490 age, sex, processing batch, methylation set, depression status⁷³ and known pQTL effects (from a
491 previous genome-wide association study of 4,034 SOMAmers targeting 3,622 proteins from Sun *et*
492 *al*)²⁴ in the basic MWAS. A second model further adjusted for estimated white blood cell
493 proportions (Monocytes, CD4⁺T cells, CD8⁺T cells, BCells, Natural Killer cells, Granulocytes and
494 Eosinophils). While Neutrophil estimates were available, they were excluded due to high correlation
495 (>95%) with Granulocyte proportions (Supplementary Fig. 22). Finally, the fully-adjusted model
496 further regressed DNAm onto an epigenetic score for smoking, EpiSmokEr⁷³ and body mass index
497 (BMI).

498 Omics-data-based complex trait analysis (OSCA)⁷⁹ Version 0.41 was used to run EWAS analyses.
499 Within OSCA, a genetic relationship matrix (GRM) was constructed for the STRADL population. A
500 threshold of 0.05 was used to identify 120 individuals likely to be related based on their genetic
501 similarity. For this reason, the MOA method was used to calculate associations between individual
502 CpG sites and protein levels, with the addition of the GRM as a random effect to adjust for

503 relatedness between individuals⁷⁹. CpG sites were the dependent variables and the 4,235 proteins
504 were the independent variables.

505 Five fully-adjusted models did not converge (NAGLU, CFHR2, DAP, MST1, PILRA) and were
506 excluded. A threshold for multiple testing correction ($P < 4.5 \times 10^{-10}$) was based on 143 independent
507 protein components with cumulative variance >80% (Supplementary Fig. 1 and Supplementary
508 Table 3) ($P < 0.05/(143 \times 772,619)$ CpGs). A more conservative threshold based on total number of
509 SOMAmers was also considered ($P < 0.05/(4,235 \times 772,619) = 1.5 \times 10^{-11}$) and is detailed in
510 Supplementary Tables 4-6. pQTM were classified as *cis* if the CpG was on the same chromosome
511 as the protein-coding gene and fell within 10Mb of the transcriptional start site (TSS) of the protein
512 gene. pQTMs involving a CpG located on a different chromosome to the protein-coding gene, or
513 >10Mb from the TSS of the protein gene were classed as *trans*.

514 Circos plots were created with the circlize package (Version 0.4.12)⁸⁰. BioRender.com was used to
515 create Figs. 1, 2, 3 and 6. All analyses were performed in R (Version 4.0)⁸¹.

516 **Functional mapping and tissue expression analyses**

517 Functional mapping and annotation (FUMA)⁸² gene set enrichment analyses were conducted for
518 genes corresponding to protein markers that were identified through the PheWAS study, in addition
519 to genes linked to either CpGs or proteins in the neurological pQTM subset. Protein-coding genes
520 were selected as the background set and ensemble v92 was used with a false discovery rate (FDR)
521 adjusted $P < 0.05$ threshold for gene set testing. For the genes corresponding to protein markers in
522 the PheWAS a minimum overlapping number of genes was set to 3, whereas this was set to 2 for the
523 genes involved in neurological pQTMs for the purposes of visualisation. The STRING⁸³ database
524 was queried to build a protein interaction network based on all proteins that had associations in the
525 PheWAS. mQTL and eQTL lookups were performed using the GoDMC⁵⁹ and eQTLGen databases

526 ⁸⁴, respectively. UCSC database searches were used to profile the positional information relating to
527 CpGs in the pQTMs involving proteins associated with brain health.

528 Although inter-chromosomal chromatin interactions are unlikely to be stable and persistent, seven
529 proteins with *cis* pQTMs involving CpGs located intra-chromosomally to the proximal protein-
530 coding gene were considered for ChIP-seq and promoter-capture Hi-C mapping to interrogate local
531 chromatin interactions and states that might form the basis for co-regulation of these loci. ChIP-seq
532 data from peripheral blood mononuclear cells (PBMCs) and brain hippocampus were selected from
533 the ENCODE project ⁸⁶, with accession identifiers available in Supplementary Table 21. Processed
534 promoter-capture Hi-C data for brain hippocampal tissue was integrated from Jung et al, ⁶⁰ and is
535 available at NCBI Geo with accession GSE86189. Data concerning both promoter-promoter
536 interactions and promoter-other interactions were concatenated and all regions subsequently
537 visualised on the WashU epigenome browser ⁸⁷.

538 **Ethics declarations**

539 All components of GS received ethical approval from the NHS Tayside Committee on Medical
540 Research Ethics (REC Reference Number: 05/S1401/89). GS has also been granted Research Tissue
541 Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20/ES/0021),
542 providing generic ethical approval for a wide range of uses within medical research.

543 **Data availability**

544 Datasets generated in this study are made available in Supplementary Tables. Source data are
545 provided with this paper.

546 Fully-adjusted MWAS summary statistics for protein levels are available through Zenodo [insert
547 details once accepted files are uploaded] and hosted on the MRC-IEU EWAS catalog [insert details
548 once accepted files are uploaded] ²⁵.

549 A YouTube video summarising the findings of the study and detailing how to access files can be
550 viewed at <https://www.youtube.com/channel/UCxQrFFtIItF25YKfJTXuumQ>.

551 The source datasets from the cohorts that were analysed during the current study are not publicly
552 available due to them containing information that could compromise participant consent and
553 confidentiality. Data can be obtained from the data owners. Instructions for accessing Generation
554 Scotland data can be found here: <https://www.ed.ac.uk/generation-scotland/for-researchers/access>;
555 the ‘GS Access Request Form’ can be downloaded from this site. Completed request forms must be
556 sent to access@generationscotland.org to be approved by the Generation Scotland Access
557 Committee.

558 **Code availability**

559 All R code used in this study is available with open access at the following Gitlab repository:
560 [https://gitlab.com/dannigadd/epigenome-and-phenome-wide-study-of-brain-health-outcomes/-](https://gitlab.com/dannigadd/epigenome-and-phenome-wide-study-of-brain-health-outcomes/-/tree/main)
561 [/tree/main](https://gitlab.com/dannigadd/epigenome-and-phenome-wide-study-of-brain-health-outcomes/-/tree/main)

562 **Acknowledgements**

563 **This research was funded in whole, or in part, by the Wellcome Trust [104036/Z/14/Z,**
564 **108890/Z/15/Z, 221890/Z/20/Z]. For the purpose of open access, the author has applied a CC**
565 **BY public copyright licence to any Author Accepted Manuscript version arising from this**
566 **submission.** D.A.G. and R.F.H. are supported by funding from the Wellcome Trust 4-year PhD in
567 Translational Neuroscience–training the next generation of basic neuroscientists to embrace clinical
568 research [108890/Z/15/Z]. R.I.M is supported by funding from the Wellcome Trust PhD for
569 clinicians, Edinburgh Clinical Academic Track for Veterinary Surgeons. D.L.Mc.C. and R.E.M. are
570 supported by Alzheimer’s Research UK major project grant ARUK-PG2017B–10. R.E.M is
571 supported by Alzheimer’s Society major project grant AS-PG-19b-010. Generation Scotland

572 received core support from the Chief Scientist Office of the Scottish Government Health Directorates
573 (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNA methylation
574 profiling of the GS samples was carried out by the Genetics Core Laboratory at the Clinical Research
575 Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK
576 and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience and Depression
577 Longitudinally” ([STRADL; Reference 104036/Z/14/Z]). Proteomic analyses in STRADL were
578 supported by Dementias Platform UK (DPUK). DPUK funded this work through core grant support
579 from the Medical Research Council [MR/L023784/2]. C.H. is supported by an MRC University Unit
580 Programme Grant MC_UU_00007/10 (QTL in Health and Disease). L.S. is funded by DPUK
581 through MRC (grant no. MR/L023784/2) and the UK Medical Research Council Award to the
582 University of Oxford (grant no. MC_PC_17215). L.S. also received support from the NIHR
583 Biomedical Research Centre at Oxford Health NHS Foundation Trust.

584 S.R.C is supported by the Medical Research Council (MR/R024065/1), a National Institutes of
585 Health research grant (R01AG054628) and a Sir Henry Dale Fellowship jointly funded by the
586 Wellcome Trust and the Royal Society (Grant Number 221890/Z/20/Z).

587 JDS is funded by MRC grants MR/S010351/1, MR/W002566/1 and MR/W002388/1. JMW is
588 supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded
589 by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. EB is
590 supported by Stroke Association/BHF/Alzheimer’s Society ‘Rates Risks and Routes to Reduce
591 Vascular Dementia’ (R4VaD) Priority Programme Award in Vascular Dementia (16 VAD 07).

592 The authors acknowledge the work of Rebecca Madden, Marco Squillace and Laura Klinkhamer
593 who aided in the quality control of volumetric brain imaging data.

594 **Author contributions**

595 D.A.G., and R.E.M., were responsible for the conception and design of the study. D.A.G. carried out
596 the data analyses. D.A.G., and R.E.M., drafted the article. S.R.C., and H.W., advised on
597 methodology. R.F.H., and D.L.Mc., contributed to methodology and data analyses. R.I.McG., S.M.,
598 R.M.W., L.S., D.L.Mc., R.M.W., A.C., A.N.H., C.H., K.L.E., D.J.P., H.W., A.M.M., and S.R.C.,
599 contributed to data methylation and proteomic data collection and preparation. A.S., M.C.B.,
600 M.A.H., E.V.B., J.D.S., S.X., C.G., and J.M.W processed the brain imaging data. D.A.O., G.M.T.,
601 and C.R., provided scientific counsel. T.C., and N.R., consulted on chromatin analyses. R.E.M.,
602 supervised the project. All authors read and approved the final manuscript.

603 **Competing interests**

604 R.E.M has received a speaker fee from Illumina and is an advisor to the Epigenetic Clock
605 Development Foundation. A.M.M has previously received speaker's fees from Illumina and Janssen
606 and research grant funding from The Sackler Trust. R.F.H. has received consultant fees from
607 Illumina. All other authors declare no competing interest.

608 **Materials and correspondence**

609 All correspondence and material requests should be sent to Dr Riccardo Marioni at
610 riccardo.marioni@ed.ac.uk.

611 **References**

- 612 1. Ly, M. *et al.* Late-life depression and increased risk of dementia: a longitudinal cohort study.
613 *Transl. Psychiatry* 2021 *111* **11**, 1–10 (2021).
- 614 2. Shi, Y. & Wardlaw, J. M. Update on cerebral small vessel disease: a dynamic whole-brain
615 disease. *Stroke Vasc. Neurol.* **1**, 83–92 (2016).
- 616 3. Biondo, F. *et al.* Brain-age predicts subsequent dementia in memory clinic patients. *medRxiv*
617 2021.04.03.21254781 (2021) doi:10.1101/2021.04.03.21254781.
- 618 4. Cox, S. R., Ritchie, S. J., Fawns-Ritchie, C., Tucker-Drob, E. M. & Deary, I. J. Structural
619 brain imaging correlates of general intelligence in UK Biobank. *Intelligence* **76**, 101376
620 (2019).
- 621 5. Corley, J. *et al.* Epigenetic signatures of smoking associate with cognitive function, brain
622 structure, and mental and physical health outcomes in the Lothian Birth Cohort 1936. *Transl.*
623 *Psychiatry* **9**, (2019).
- 624 6. Stillman, C. M., Weinstein, A. M., Marsland, A. L., Gianaros, P. J. & Erickson, K. I. Body–
625 Brain Connections: The Effects of Obesity and Behavioral Interventions on Neurocognitive
626 Aging. *Front. Aging Neurosci.* **9**, 115 (2017).
- 627 7. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2020 report of the Lancet
628 Commission. *The Lancet* vol. 396 413–446 (2020).
- 629 8. Lindbohm, J. V *et al.* Association of plasma proteins with rate of cognitive decline and
630 dementia: 20-year follow-up of the Whitehall II and ARIC cohort studies. *medRxiv*
631 2020.11.18.20234070 (2020) doi:10.1101/2020.11.18.20234070.
- 632 9. Walker, K. A. *et al.* Large-scale plasma proteomic analysis identifies proteins and pathways

- 633 associated with dementia risk. *Nat. Aging* **1**, 473–489 (2021).
- 634 10. Sebastiani, P. *et al.* A serum protein signature of APOE genotypes in centenarians. *Aging Cell*
635 **18**, e13023 (2019).
- 636 11. Berson, A., Nativio, R., Berger, S. L. & Bonini, N. M. Epigenetic Regulation in
637 Neurodegenerative Diseases. *Trends Neurosci.* **41**, 587 (2018).
- 638 12. Al-Mahdawi, S., Virmouni, S. A. & Pook, M. A. The emerging role of 5-
639 hydroxymethylcytosine in neurodegenerative diseases. *Front. Neurosci.* **8**, 397 (2014).
- 640 13. Lea, A. J. *et al.* Genome-wide quantification of the effects of DNA methylation on human
641 gene regulation. *Elife* eLife 2018;7:e37513 (2018) doi:10.7554/eLife.37513.
- 642 14. Zaghlool, S. B. *et al.* Epigenetics meets proteomics in an epigenome-wide association study
643 with circulating blood plasma protein traits. *Nat. Commun.* **11**, 15 (2020).
- 644 15. Hillary, R. F. *et al.* Multi-method genome- And epigenome-wide studies of inflammatory
645 protein levels in healthy older adults. *Genome Med.* **12**, 60 (2020).
- 646 16. Hillary, R. F. *et al.* Genome and epigenome wide studies of neurological protein biomarkers in
647 the Lothian Birth Cohort 1936. *Nat. Commun.* **10**, 3160 (2019).
- 648 17. Conole, E. L. S. *et al.* DNA Methylation and Protein Markers of Chronic Inflammation and
649 Their Associations With Brain and Cognitive Aging. *Neurology* **97**, e2340–e2352 (2021).
- 650 18. Gadd, D. A. *et al.* Epigenetic scores for the circulating proteome as tools for disease
651 prediction. *Elife* **11**, (2022).
- 652 19. Hillary, R. F. *et al.* Genome and epigenome wide studies of plasma protein biomarkers for
653 Alzheimer’s disease implicate TBCA and TREM2 in disease risk. *medRxiv*

- 654 2021.06.07.21258457 (2021) doi:10.1101/2021.06.07.21258457.
- 655 20. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 656 21. Houseman, E. A. *et al.* DNA methylation arrays as surrogate measures of cell mixture
657 distribution. *BMC Bioinformatics* **13**, 86 (2012).
- 658 22. McCartney, D. L. *et al.* Epigenetic signatures of starting and stopping smoking. *EBioMedicine*
659 **37**, 214–220 (2018).
- 660 23. McCartney, D. L. *et al.* Epigenetic prediction of complex traits and death. *Genome Biol.* **19**,
661 136 (2018).
- 662 24. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 663 25. MRC-IEU. The MRC-IEU catalog of epigenome-wide association studies. Available at:
664 <http://www.ewascatalog.org>. Accessed April 2021. (2021).
- 665 26. Saffari, A. *et al.* Estimation of a significance threshold for epigenome-wide association
666 studies. **42**, 22–23 (2017).
- 667 27. Ferkingstad, E. *et al.* Large-scale integration of the plasma proteome with genetics and
668 disease. *Nat. Genet.* 2021 5312 **53**, 1712–1721 (2021).
- 669 28. Lehallier, B. *et al.* Undulating changes in human plasma proteome profiles across the lifespan.
670 *Nat. Med.* **25**, 1843–1850 (2019).
- 671 29. Harris, S. E. *et al.* Neurology-related protein biomarkers are associated with cognitive ability
672 and brain volume in older age. *Nat. Commun.* **11**, 1–12 (2020).
- 673 30. Shi, L. *et al.* Identification of plasma proteins relating to brain neurodegeneration and vascular
674 pathology in cognitively normal individuals. *Alzheimer's Dement. Diagnosis, Assess. Dis.*

- 675 *Monit.* **13**, (2021).
- 676 31. Jefferson, A. L. *et al.* Inflammatory biomarkers are associated with total brain volume: The
677 Framingham Heart Study. *Neurology* **68**, 1032–1038 (2007).
- 678 32. Janowitz, D. *et al.* Inflammatory markers and imaging patterns of advanced brain aging in the
679 general population. *Brain Imaging Behav.* **14**, 1108–1117 (2020).
- 680 33. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association
681 study of educational attainment in 1.1 million individuals. *Nat. Genet.* **50**, 1112–1121 (2018).
- 682 34. Conole, E. L. S. *et al.* An epigenetic proxy of chronic inflammation outperforms serum levels
683 as a biomarker of brain ageing. medRxiv. (2020)
684 doi:<https://doi.org/10.1101/2020.10.08.20205245>.
- 685 35. C, G. *et al.* Structural brain correlates of serum and epigenetic markers of inflammation in
686 major depressive disorder. *Brain. Behav. Immun.* **92**, 39–48 (2021).
- 687 36. Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M. & Erickson, M. A. Healthy aging and
688 the blood–brain barrier. doi:10.1038/s43587-021-00043-5.
- 689 37. Montagne, A. *et al.* Blood-Brain Barrier Breakdown in the Aging Human Hippocampus.
690 *Neuron* **85**, 296 (2015).
- 691 38. Beaubien, F., Raja, R., Kennedy, T. E., Fournier, A. E. & Cloutier, J. F. Slitrk1 is localized to
692 excitatory synapses and promotes their development. *Sci. Reports 2016 61* **6**, 1–10 (2016).
- 693 39. Schmidt, S., Arendt, T., Morawski, M. & Sonntag, M. Neurocan Contributes to Perineuronal
694 Net Development. *Neuroscience* **442**, 69–86 (2020).
- 695 40. Madetko, N. *et al.* Anti-IgLON5 Disease – The Current State of Knowledge and Further

- 696 Perspectives. *Front. Immunol.* **0**, 777 (2022).
- 697 41. Vallerga, C. L. *et al.* Analysis of DNA methylation associates the cystine–glutamate antiporter
698 SLC7A11 with risk of Parkinson’s disease. *Nat. Commun.* **11**, 1–10 (2020).
- 699 42. Fournier, M. *et al.* Implication of the glutamate-cystine antiporter xCT in schizophrenia cases
700 linked to impaired GSH synthesis. *npj Schizophr.* **3**, 1–7 (2017).
- 701 43. Mesci, P. *et al.* System xC⁻ is a mediator of microglial function and its deletion slows
702 symptoms in amyotrophic lateral sclerosis mice. *Brain* **138**, 53–68 (2015).
- 703 44. Lohoff, F. W. *et al.* Epigenome-wide association study of alcohol consumption in N = 8161
704 individuals and relevance to alcohol use disorder pathophysiology: identification of the
705 cystine/glutamate transporter SLC7A11 as a top target. *Mol. Psychiatry* (2021)
706 doi:10.1038/S41380-021-01378-6.
- 707 45. Wood, G. C. *et al.* A multi-component classifier for nonalcoholic fatty liver disease (NAFLD)
708 based on genomic, proteomic, and phenomic data domains. *Sci. Rep.* **7**, (2017).
- 709 46. Zhuang, J., Deane, J. A., Yang, R. B., Li, J. & Ricardo, S. D. SCUBE1, a novel developmental
710 gene involved in renal regeneration and repair. *Nephrol. Dial. Transplant.* **25**, 1421–1428
711 (2010).
- 712 47. Ho, J. C. Y. *et al.* Down-regulation of retinol binding protein 5 is associated with aggressive
713 tumor features in hepatocellular carcinoma. *J. Cancer Res. Clin. Oncol.* **133**, 929–936 (2007).
- 714 48. Hop, P. J. *et al.* Genome-wide study of DNA methylation shows alterations in metabolic,
715 inflammatory, and cholesterol pathways in ALS. *Sci. Transl. Med.* **14**, 36 (2022).
- 716 49. Park, M. H., Jin, H. K. & Bae, J. sung. Potential therapeutic target for aging and age-related

- 717 neurodegenerative diseases: the role of acid sphingomyelinase. *Exp. Mol. Med.* **52**, 380–389
718 (2020).
- 719 50. Lee, J. K. *et al.* Acid sphingomyelinase modulates the autophagic process by controlling
720 lysosomal biogenesis in Alzheimer’s disease. *J. Exp. Med.* **211**, 1551–1570 (2014).
- 721 51. Kyrkanides, S. *et al.* Conditional expression of human β -hexosaminidase in the neurons of
722 Sandhoff disease rescues mice from neurodegeneration but not neuroinflammation. *J.*
723 *Neuroinflammation* **9**, 186 (2012).
- 724 52. Bley, A. E. *et al.* Natural history of infantile G M2 gangliosidosis. *Pediatrics* **128**, e1233
725 (2011).
- 726 53. Hamshere, M. L. *et al.* Genome-wide significant associations in schizophrenia to ITIH3/4,
727 CACNA1C and SDCCAG8, and extensive replication of associations reported by the
728 Schizophrenia PGC. *Mol. Psychiatry* **18**, 708–712 (2013).
- 729 54. Witt, S. H. *et al.* Investigation of manic and euthymic episodes identifies state-and trait-
730 specific gene expression and stab1 as a new candidate gene for bipolar disorder. *Transl.*
731 *Psychiatry* **4**, 426 (2014).
- 732 55. Ripke, S. *et al.* Genome-wide association study identifies five new schizophrenia loci. *Nat.*
733 *Genet.* **43**, 969–978 (2011).
- 734 56. Sklar, P. *et al.* Large-scale genome-wide association analysis of bipolar disorder identifies a
735 new susceptibility locus near ODZ4. *Nat. Genet.* **43**, 977–985 (2011).
- 736 57. Davies, G. *et al.* Study of 300,486 individuals identifies 148 independent genetic loci
737 influencing general cognitive function. *Nat. Commun.* **9**, 1–16 (2018).

- 738 58. Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals identifies
739 new genetic and functional links to intelligence. *Nat. Genet.* **50**, 912–919 (2018).
- 740 59. Min, J. L. *et al.* Genomic and phenotypic insights from an atlas of genetic effects on DNA
741 methylation. *Nat. Genet.* **53**, 1311–1321 (2021).
- 742 60. Jung, I. *et al.* A Compendium of Promoter-Centered Long-Range Chromatin Interactions in the
743 Human Genome. *Nat. Genet.* **51**, 1442 (2019).
- 744 61. Héberlé, É. & Bardet, A. F. Sensitivity of transcription factors to DNA methylation. *Essays*
745 *Biochem.* **63**, 727 (2019).
- 746 62. Arechederra, M. *et al.* Hypermethylation of gene body CpG islands predicts high dosage of
747 functional oncogenes in liver cancer. *Nat. Commun.* **2018 91 9**, 1–16 (2018).
- 748 63. Salas, L. A. *et al.* Enhanced cell deconvolution of peripheral blood using DNA methylation
749 for high-resolution immune profiling. *Nat. Commun.* **2022 131 13**, 1–13 (2022).
- 750 64. Pietzner, M. *et al.* Genetic architecture of host proteins involved in SARS-CoV-2 infection.
751 *Nat. Commun.* **11**, 6397 (2020).
- 752 65. Yang, C. *et al.* Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins
753 implicated in neurological disorders. *Nat. Neurosci.* **2021 249 24**, 1302–1312 (2021).
- 754 66. Braun, P. R. *et al.* Genome-wide DNA methylation comparison between live human brain and
755 peripheral tissues within individuals. *Transl. Psychiatry* **2019 91 9**, 1–10 (2019).
- 756 67. Smith, B. H. *et al.* Cohort profile: Generation scotland: Scottish family health study (GS:
757 SFHS). The study, its participants and their potential for genetic research on health and illness.
758 *Int. J. Epidemiol.* **42**, 689–700 (2013).

- 759 68. Habota, T. *et al.* Cohort profile for the STRatifying Resilience and Depression Longitudinally
760 (STRADL) study: A depression-focused investigation of Generation Scotland, using detailed
761 clinical, cognitive, and neuroimaging assessments. *Wellcome Open Res.* **4**, 185 (2019).
- 762 69. Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery.
763 *PLoS One* **5**, e15004 (2010).
- 764 70. Seeboth, A. *et al.* DNA methylation outlier burden, health, and ageing in Generation Scotland
765 and the Lothian Birth Cohorts of 1921 and 1936. *Clin. Epigenetics* **12**, 49 (2020).
- 766 71. McCartney, D. L. *et al.* Investigating the relationship between DNA methylation age
767 acceleration and risk factors for Alzheimer’s disease. *Alzheimer’s Dement. Diagnosis, Assess.*
768 *Dis. Monit.* **10**, 429–437 (2018).
- 769 72. Amador, C. *et al.* Recent genomic heritage in Scotland. *BMC Genomics* **16**, 437 (2015).
- 770 73. Bollepalli, S., Korhonen, T., Kaprio, J., Anders, S. & Ollikainen, M. EpiSmokEr: A robust
771 classifier to determine smoking status from DNA methylation data. *Epigenomics* **11**, 1469–
772 1486 (2019).
- 773 74. Min, J. L., Hemani, G., Davey Smith, G., Relton, C. & Suderman, M. Meffil: efficient
774 normalization and analysis of very large DNA methylation datasets. *Bioinformatics* **34**, 3983–
775 3989 (2018).
- 776 75. Reinius, L. E. *et al.* Differential DNA Methylation in Purified Human Blood Cells:
777 Implications for Cell Lineage and Studies on Disease Susceptibility. *PLoS One* **7**, e41361
778 (2012).
- 779 76. A, S. *et al.* Automated classification of depression from structural brain measures across two
780 independent community-based cohorts. *Hum. Brain Mapp.* **41**, 3922–3937 (2020).

- 781 77. Therneau, T. M. *coxme*: Mixed Effects Cox Models. R package version 2.2-16.
782 <https://CRAN.R-project.org/package=coxme>. Accessed April 2021. (2020).
- 783 78. *prcomp* function - RDocumentation.
784 <https://www.rdocumentation.org/packages/stats/versions/3.6.2/topics/prcomp>.
- 785 79. Zhang, F. *et al.* OSCA: A tool for omic-data-based complex trait analysis. *Genome Biol.* **20**,
786 (2019).
- 787 80. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. *circlize* implements and enhances circular
788 visualization in R. *Bioinformatics* **30**, 2811–2812 (2014).
- 789 81. (2017), R. C. T. R: A language and environment for statistical computing. R Foundation for
790 Statistical Computing, Vienna, Austria.
- 791 82. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and
792 annotation of genetic associations with FUMA. *Nat. Commun.* **2017 81 8**, 1–11 (2017).
- 793 83. Szklarczyk, D. *et al.* The STRING database in 2021: customizable protein–protein networks,
794 and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.*
795 **49**, D605–D612 (2021).
- 796 84. Vösa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and
797 polygenic scores that regulate blood gene expression. *Nat. Genet.* **2021 539 53**, 1300–1310
798 (2021).
- 799 85. Kent, W. *et al.* UCSC Genome Browser: The human genome browser at UCSC. *Genome Res.*
800 **12**, 996–1006 (2002).
- 801 86. Sloan, C. A. *et al.* ENCODE data at the ENCODE portal. *Nucleic Acids Res.* **44**, D726–D732

802 (2016).

803 87. Li, D., Hsu, S., Purushotham, D., Sears, R. L. & Wang, T. WashU Epigenome Browser update
804 2019. *Nucleic Acids Res.* **47**, W158–W165 (2019).

805

806

807 **Figure legends**

808 **Figure 1. Integrated methylome and phenome study of the plasma proteome in relation to**
809 **brain health.** Study design and key results are presented in this flow diagram. 1,065 individuals
810 from Generation Scotland had the levels of 4,058 plasma proteins (corresponding to 4,235
811 SOMAmers) measured. A methylome-wide association study (MWAS) of the 4,058 plasma protein
812 levels was conducted in 774 individuals that represented a nested subset of the full sample with
813 DNAm measurements available. This identified 2,928 CpG-protein (pQTM) associations. A
814 phenome-wide protein association study (Protein PheWAS) identified 191 protein levels that were
815 associated with a minimum of one brain health trait ($N \geq 909$). Integration of the protein MWAS and
816 PheWAS results identified 35 pQTMs that involved the levels of 17 protein markers of brain health
817 and 31 unique CpGs located in 20 genes.

818 **Figure 2. Methylome-wide studies of 4,058 plasma proteins. a** Summary of MWAS results for
819 4,058 protein levels in Generation Scotland ($N=774$). MWAS pQTMs that had $P < 4.5 \times 10^{-10}$ in the
820 basic, white blood cell proportion (WBC)-adjusted and fully-adjusted models. *Cis* associations
821 (purple) and *trans* associations (green) are summarised for each model. Covariates used to adjust
822 DNAm are described for each model. Protein levels were adjusted for age, sex, 20 genetic principal
823 components (PCs) and technical variables and normalised prior to running MWAS. **b** Flow diagram
824 showing the distinction between the highly pleiotropic PAPP A and PRG3 protein pQTMs and the
825 825 pQTMs that involved the levels of a further 189 proteins. **c** Genomic locations for 825 of the
826 2,928 fully-adjusted pQTMs, excluding highly pleiotropic associations for PAPP A and PRG3 protein
827 levels. Chromosomal location of CpG sites (x-axis) and protein genes (y-axis) are presented. The 434
828 *cis* pQTMs (purple) lay on the same chromosome and ≤ 10 Mb from the transcriptional start site
829 (TSS) of the protein gene, whereas the 391 *trans* pQTMs (green) lay > 10 Mb from the TSS of the


830 protein gene or on a different chromosome. A list of the full association counts for each protein and
831 CpG site can be found in Supplementary Tables 8-9.

832 **Figure 3. Pleiotropic associations in the fully-adjusted MWAS.** **a** pQTM that had $P < 4.5 \times 10^{-10}$
833 in the fully-adjusted MWAS are plotted as individual points with chromosomal locations of the 191
834 protein genes (upper) and the 1,837 CpGs (lower) on the x-axis. 19 proteins with ≥ 10 associations
835 with CpGs are highlighted in turquoise and labelled on the upper plot. Nine CpGs with ≥ 6
836 associations with protein levels are highlighted in turquoise on the lower plot. **b** Summary of genes
837 with highly pleiotropic CpG signals in the fully-adjusted MWAS. The fully-adjusted MWAS pQTM
838 can be accessed in Supplementary Table 6. A list of the full association counts for each protein and
839 CpG site can be found in Supplementary Tables 8-9.

840 **Figure 4. PheWAS of 4,058 plasma proteins and brain health.** **a** Number of protein marker
841 associations with $P < 3.5 \times 10^{-4}$ for each of the 15 traits related to brain health in the genome-wide
842 protein association studies (protein PheWAS). These studies included a maximum sample of 1,065
843 individuals with protein measurements from Generation Scotland and tested for associations between
844 15 phenotypes and the levels of 4,058 plasma proteins. Cognitive score (turquoise), brain imaging
845 (light blue) and *APOE* e4 status (dark blue) associations are summarised. **b** Heatmap of standardised
846 beta coefficients for 77 of the 405 protein PheWAS associations ($P < 3.5 \times 10^{-4}$) indicated by an
847 asterisk. They include three proteins that had associations with both *APOE* e4 status and one or more
848 cognitive scores, in addition to 22 proteins that had associations with both a brain imaging measure
849 and a cognitive score. Negative and positive beta coefficients are shown in blue and red,
850 respectively. A heatmap describing the full 405 associations for *APOE* e4 status, cognitive scores
851 and brain imaging measures is available in Supplementary Fig. 6. Full summary statistics for the 405
852 associations are presented in Supplementary Table 17 and the subset of 77 associations shown in part
853 **b** can be accessed in Supplementary Table 18.

854 **Figure 5. pQTM involving protein markers of brain health.** Circular plot showing 15 *trans*
855 pQTM associations between DNAm at 11 CpG sites and the levels of nine proteins that were
856 associated with one of more of the neurological phenotypes ($P < 3.5 \times 10^{-4}$). Chromosomal positions
857 are given on the outermost circle. Full details of the 35 pQTMs, including 20 *cis* associations are
858 reported in Supplementary Table 20.

859 **Figure 6. Integration of candidate marker associations.** **a** Three *trans* associations with the CpG
860 site cg06690548 in the *SLC7A11* gene, which encodes a synaptic protein that is linked to
861 environmental mediation in Parkinson's disease and is involved in glutamate transmission and
862 oxidative stress. **b** Five *trans* associations between CpGs in the *ITIH3/ITIH1/NEK4* region on
863 chromosome 3 and the levels of RBL2, which was associated with reductions in Global Grey Matter
864 Volume. **c** Two *trans* associations between DNAm at cg11294350 in the *CHPT1* gene and two
865 proteins with lysosomal-associated function (SMPD1 and HEXB) that were associated with higher
866 Relative Brain Age and lower General Fractional Anisotropy. Associations with a positive beta
867 coefficient are denoted as red connecting lines, whereas associations with a negative beta coefficient
868 are denoted as blue connecting lines. The full 15 *trans* associations and 20 *cis* associations can be
869 found in Supplementary Table 20.



a

Basic MWAS

DNAm adjusted for: Age, Sex, Depression, DNAm Set/Batch

238,245 pQTM

2,107 *cis*236,138 *trans***White blood cell (WBC)-adjusted MWAS**

+ estimated WBC proportions

3,213 pQTM

453 *cis*2,760 *trans***Fully-adjusted MWAS**

+ BMI and a DNAm-based smoking score (EpiSmokEr)

2,928 pQTM

451 *cis*2,477 *trans*

Protein levels adjusted for: Age, Sex, pQTLs, technical covariates, 20 genetic PCs

Association threshold: $P < 4.5 \times 10^{-10}$

N=774 individuals, N=4,058 protein levels (4,235 SOMAmer measurements)

b

Fully-adjusted MWAS

2,928 pQTM

451 *cis* 2,477 *trans*987 pQTM
PAPPA825 pQTM
189 proteins1116 pQTM
PRG3434 *cis*391 *trans*


CpG


CpG

- Same chromosome
- ≤ 10 Mb from TSS


- Different chromosome
- > 10 Mb from TSS

c



a**b**

Regulation of immune activity




cg07839457
cg16411857

NLRC5

LAG3, FCGR3B, CD48, CECR1, GBP1, CD163, LY9, CSF1R, CRTAM, GZMA, CD5L, IL18BP, IL15RA, IL12B, VCAM1, B2M, TNFRSF1B, CXCL11

FCGR3B, CECR1, CD163, GBP1, LAG3, CSF1R, CD48, VCAM1

Synaptic cystine-glutamate transporter, oxidative stress




cg13903162
cg06690548

SLC7A11

PAPP, PRG3

PSAT1, SCUBE1, PRSS2, ALDOB, ACY1, APOC3, ADSSL1, DEFB1, RBP5

DNA damage repair and immune function



cg08122652
cg00959259
cg07815522
cg22930808



PARP9

MX1, ISG15, GBP1, CXCL11, LAG3, DDX58, CD48, IFIT3, STAT1, B2M

MX1, ISG15, GBP1, LAG3, CD48

ISG15, MX1, GBP1, CXCL11, DDX58

MX1, GBP1, ISG15, DDX58, CXCL11

a**b****c**